Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12weeks in patients with Type2 diabetes: Dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study

Diabetic Medicine

Volumn 29, Issue 10, 2012, Pages 1260-1267

  Grunberger, G ^a   Chang, A ^b   Garcia Soria, G ^c   Botros, F T ^d   Bsharat, R ^d   Milicevic, Z ^d  

^a Grunberger Diabetes Institute   (United States)

^b John Muir Physician Network Clinical Research Center   (United States)

^c IMIC Research   (Mexico)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DULAGLUTIDE; HEMOGLOBIN A1C; METFORMIN; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CHOLELITHIASIS; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HEMORRHAGIC PANCREATITIS; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TREATMENT DURATION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FASTING; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS;

EID: 84866435806     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2012.03745.x     Document Type: Article

References (18)

1. Verspohl EJ. Novel therapeutics for type2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther 2009; 124: 113-138.
2. Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM et al. Efficacy and tolerability of exenatide monotherapy over 24weeks in antidiabetic drug-naive patients with type2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008; 30: 1448-1460.
3. Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges JP et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy, significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type2 diabetes. Diabetes Care 2007; 30: 1608-1610.
4. Aschner P, Katzeff HL, Guo H, Sunga S, Williams-Herman D, Kaufman KD et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type2 diabetes. Diabetes Obes Metab 2010; 12: 252-261.
5. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type2 diabetes. Diabetes Care 2007; 30: 1487-1493.
6. Matthews JE, Stewart MW, De Boever EH, Dobbins RL, Hodge RJ, Walker SE et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type2 diabetes. J Clin Endocrinol Metab 2008; 93: 4810-4817.
7. Rosenstock J, Reusch J, Bush M, Yang F, Stewart M. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009; 32: 1880-1886.
8. Glaesner W, Vick AM, Millican R, Ellis B, Tschang SH, Tian Y et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev 2010; 26: 287-296.
9. Barrington P, Chien JY, Showalter HD, Schneck K, Cui S, Tibaldi F et al. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analog, in patients with type2 diabetes. Diabetes Obes Metab 2011; 13: 426-433.
10. ADA. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28: 1245-1249.
11. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-1495.
12. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type2 diabetes after once-daily treatment with the long-acting glucagon-like peptide1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004; 27: 1335-1342.
13. Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan DM, Peterson CM. Tests of glycemia in diabetes. Diabetes Care 2004; 27: S91-S93.
14. Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson JH, Bastyr EJ 3rd. The effects of LY2189265, a long-acting glucagon-like peptide-1 analog, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type2 diabetes: the EGO study. Diabetes Obes Metab 2011; 13: 418-425.
15. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D et al. Exenatide once weekly versus twice daily for the treatment of type2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240-1250.
16. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I et al. Liraglutide versus glimepiride monotherapy for type2 diabetes (LEAD-3 Mono): a randomised, 52-week, phaseIII, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-481.
17. Bastyr EJ, Barkin J, Botros FT, Shu J. High incidence of elevated lipase and amylase in Type2 diabetes patients (T2DM). Pancreas 2009; 38: 980-1067.
18. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32: 84-90.